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Eicosanoids are signaling molecules that control the immune processes and might have effects on inflammatory 
diseases. The aim of our study was to evaluate the effect of added resolvin D2 (RvD2), after treatment with polycyclic 
aromatic hydrocarbons (PAHs), on RAW 264.7 cells by using a UHPLC/MS-TOF method for the quantification of 
eicosanoids: 8-iPGF3α, PGF3α, 8-isoPGF2α PGF2α and 5-iPF2α as well as cyclooxygenase 2 (COX-2), prostaglandin E 
synthase (cPGES) and prostaglandin F2α (FP) receptor protein expression by Western blot. The levels of PGF3α, PGF2α 
8-iPGF3α 8-isoPGF2α and 5-iPF2α were decreased in RAW 264.7 cells after the exposure to PAHs and treatment with 
RvD2. It was observed that COX-2, cPGES and FP-receptor expression was decreased after co-treatment of the cells 
with PAHs and RvD2. Our findings suggest that RvD2 has anti-oxidant, anti-inflammatory and pro-resolving proper-
ties that may contribute significantly to alleviation of the harmful effects caused by PAHs in macrophages. Moreover, 
these results suggest that a diet rich in n-3 fatty acids might be helpful in resolving the inflammation and mitigating 
the effects of environmental stress in macrophages.
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INTRODUCTION
Macrophages are essential in physiological pro-
cesses including the regulation of innate and 
adaptive immunity, but they are also important 
in pathological and inflammatory states. These 
immune cells possess remarkable plasticity and 
display various shades of functionalities based 
on changes in the surrounding molecular envi-
ronment (KORNS et al., 2011). Macrophages can 
respond to danger signals through upregulation 
of proteins and synthesis of eicosanoids and other 
lipid molecules that altogether act to recruit other 
immune cells to a site of inflammation (NORRIS 
and DENNIS, 2012). Additionally, macrophages 
possess the ability to promote tissue repair once 
infection has been thwarted (KORNS et al., 2011). 
Eicosanoids are specific biomarkers of inflam-
mation. Their biosynthesis from polyunsaturated 
fatty acids can be catalysed by cyclooxygenase 
(COX-2), lipoxygenases (LOX), and cytochrome 
P450 enzymes (SEHRAN and PETASIS, 2011; SEHRAN, 
2014). Eicosanoids are potent lipid mediators of 
inflammation and are known to play an important 
role in numerous pathophysiological processes 
(GROEGER et al., 2010; LEE et al., 2013; SEHRAN, 
2014). 
Eicosanoid metabolism has been well charac-
terized using purified enzymes and overexpres-
sion studies. Currently, most interest in the field 
has shifted to defining the pathway in cellular 
inflammatory contexts. The understanding of 
the complex networks of eicosanoid metabolism 
and signaling at the physiological and patho-
logical states remains to be extremally important 
(SHERAN, 2014). 
Exposure to polycyclic aromatic hydrocarbons 
(PAHs) usually occurs by breathing contaminated 
air or by eating grilled foods. As a ligand for the 
aryl hydrocarbon receptor (AhR), BaP and other 
PAHs up-regulate the expression of phase I bioac-
tivation and phase II conjugation genes. Induction 
of biotransformation enzymes, including CYP1A1, 
CYP1B1 and epoxide hydrolase, metabolically 
activate BaP to different types of metabolites, 
including hydroxylated intermediates, epox-
ides and various metabolite-conjugates in cells 
(KANG et al., 2011; KIM et al., 2013). PAHs toxicity 
results from the bioactivation to the ultimate toxic 
epoxide compound and oxidative stress. There is 
strong evidence to suggest that oxidative stress 
is one of the most potent inductors of vascular 
inflammation in atherogenesis. Reactive oxygen 
species are known to change the redox state of 
exposed cells, and it is known that several inflam-
matory genes and the related transcription fac-
tors are regulated through redox-sensitive mecha-
nisms (JI et al., 2013).
Studies over the last four decades have shown 
that diet can modulate the response of organ-
isms to drug absorption, distribution, metabo-
lism, and excretion. An important mechanism for 
the health-promoting effects of n-3 polyunsatu-
rated fatty acids (PUFAs) is the suppression of 
the pro-inflammatory metabolism of arachidonic 
acid (AA). Eicosapentaenoic acid (EPA) and doc-
osahexaenoic acid (DHA) and their derivatives 
act as anti-inflammatory and pro-resolving com-
pounds, inhibit the formation of AA derivatives 
via multiple mechanisms (DAVIDSON et al., 2012; 
COLAS et al., 2014; SPITE et al., 2014). Endogenous 
mediators of inflammation and the mechanisms 
involved in regulating this process and its res-
olution are of wide interest (SPITE et al., 2014; 
GDULA-ARGASIŃSKA et al., 2015a,b,c). 
DHA is converted through a series of enzy-
matic oxygenations to protectins and D series 
resolvins. Resolvin D2 (7(S),16(R),17(S)-
trihydroxy-DHA, RvD2) is produced physiologi-
cally from the sequential oxygenation of DHA by 
15- and 5-lipoxygenase and is a product of trans-
cellular biosynthesis with human leukocytes and 
endothelial cells (SUN et al., 2007; SEHRAN and 
PETASIS, 2011; SEHRAN, 2014). Resolvins D are 
specialized pro-resolving mediators showing dose-
dependent actions on inflammatory signaling. 
Resolvins also specifically interact with human 
phagocytes via the ALX and GPR32 receptors. 
The mechanisms through which resolvins exert 
their biological actions involve down-regulation of 
NF-κB and AP-1 activity as well as PPARs path-
ways (CHATTERJEE et al., 2014). 
The aim of this study was to evaluate the anti-
inflammatory or pro-resolving impact of RvD2 on 
the inflammation-related genes and proteins in 
the RAW 264.7 cells exposed to PAHs.
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MATERIALS AND METHODS
Reagents
Prostaglandin F3α (PGF3α), 8-iso prostaglan-
din F3α (8-iPGF3α), 8-iso prostaglandin F2α 
(8-iPGF2α), 5-isoprostane F2α (5-iPF2α), prosta-
glandin F2α-d9 (PGF2α -d9) and 8-iso prostaglan-
din F2α-d4 (8iPGF2α -d4), RvD2 were obtained 
from Cayman Chemical Company (Michigan, 
USA). LC-MS grade methanol, ethanol, electro-
spray calibrate solution, butylated hydroxy-
toluene (BHT), PAHs, potassium hydroxide, 
hydrogen peroxide, dimethyl sulfoxide (DMSO) 
were purchased from Sigma-Aldrich (St. Louis, 
USA). Analytical grade formic acid, chloroform, 
n-hexane were supplied by Merck (Darmstadt, 
Germany). Water (18.2 MΩcm, TOC< 5ppm) was 
ultrapurified and filtered through a Milli-Q Plus 
system (Millipore, Bedford, USA).
Cultured cells
Mus musculus murine macrophages (RAW 264.7, 
TIB-71, ATCC, USA) were cultured in Dulbecco’s 
Modified Eagle’s Medium supplemented with 
10% FBS and 1% antibiotic solution (100 IU/
mL penicillin, 0.1 μg/mL streptomycin) (ATTC). 
The cells were maintained at 37oC in a humidi-
fied atmosphere of 5% CO2 in air and were finally 
seeded into a 6-well plate (Sarstedt, Germany) at 
a density of 5 x 105 cells/well in 2 mL of medium. 
At every step of the procedure, cell morphology 
was investigated by an inverted light microscope 
(Olympus, Japan). Cell viability during culturing 
was assessed with a Trypan Blue Exclusion Test. 
RAW 264.7 were treated with 1μmol of benzo(a)
pyrene (BaP), chrysene (Chr), fluoranthene (Flu) 
and benzo(a)anthracene (Baa) (Sigma-Aldrich, 
USA) for 1h and after incubation 40nmol of 
resolvin D2 (Cayman Chemical) was added for 
30min. PAHs were dissolved in DMSO. RvD2 was 
dissolved in ethanol. Control cultures received the 
same concentration of ethanol (the final content 
did not exceed 0.12% v/v) and DMSO (the final 
content did not exceed 0.05% v/v) as the experi-
mental cells. After incubation, media and the cells 
after scrapping were collected. 
ApoTox-Glo Triplex Assay
After treatment of the cells, the ApoTox-Glo Assay 
was used to assess cell viability, the potential 
cytotoxicity of RvD1, BaP, Bbf, Bkf and Pyr, and 
cell apoptosis. The assay was performed as per 
manufacturer instuctions (Promega, USA) as 
described previously (GDULA-ARGASIŃSKA et al., 
2015a). 
Isolation of isoprostanes 
Isolation of isoPs was done according to the meth-
od proposed by MILNE et al. (2006). Prior to extrac-
tion, 10 μL of 0.01% BHT was added to each sam-
ple to prevent further oxidation. Then, PGF2α-d9 
and 8iPGF2α-d4 (20 ng/μL) were added to the 
samples as an internal standard. Solid phase 
extraction (SPE) was done using Bond Elute 
Plexa cartridges (Agilent Technologies). Next, SPE 
samples were reconstituted in 200 μL of metha-
nol containing 5% formic acid prior to UHPLC/
MS-TOF analysis.
UHPLC/MS-TOF conditions
Identification and determination of isoprostanes 
were performed using an UltiMate 3000 RS liq-
uid chromatography system (Dionex, USA) cou-
pled to a mass spectrometer with a time-of-flight 
mass analyzer (MicroTOF-Q II, Bruker, Germany). 
Separation of the studied prostaglandins was car-
ried out on a Synergi 4μ Hydro-RP 80A column 
(150 x 2,0 mm I.D, Phenomenex, USA) at 40°C. 
The mobile phase was prepared by mixing metha-
nol and 0.01% formic acid according to a gradi-
ent program. The [M-H]- masses with the defined 
retention time (Rt) for the studied IsoPs were: 
8-iPGF3α m/z=351.217±0.005 (Rt=16.3 min), 
PGF3α m/z= 351.217±0.005 (Rt=17.1 min), 
8-iPGF2α m/z=353.232±0.005 (Rt=17.2 min), 
5-iPF2α m/z=353.232±0.005 (Rt=17.4 min), 
PGF2α-d9 m/z=362.289±0.005 (Rt=17.2 min), 
8iPGF2α-d4 m/z=357.257±0.005 (Rt=18.0 min). 
The details of the method were described previ-
ously (GDULA-ARGASIŃSKA et al., 2013).
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Western blot for quantity of COX – 2, 
cPGES and FP receptor 
Cell lysates were prepared using M-PER mamma-
lian protein extraction reagent (Thermo Scientific, 
USA) with protease inhibitor cocktail set III 
(Calbiochem, Merck, Germany). Protein concentra-
tions were determined using the Bradford reaction. 
Aliquots (50μg) will be solubilised in a Laemmli 
buffer with 2% mercaptoethanol (BioRad) and sub-
jected to 10% SDS-polyacrylamide gel electropho-
resis as described below (GDULA-ARGASIŃSKA 
et al., 2015b). We used primary antibodies: anti-
cyclooxygenase-2 (COX-2), anti-prostaglandin E 
synthase, anti-GAPDH diluted 1:1000 in Signal+ for 
Western Blot (GeneTex) and FP receptor (Cayman 
Chemical) diluted 1:200 in Signal+, and secondary 
antibody Easy Blot anti rabbit IgG (HRP) (GeneTex, 
1:2000). Proteins were detected using the Western 
blotting detection kit Clarity Western ECL Luminol 
Substrate (Bio-Rad, USA). The integrated optical 
density of the bands were quantified using Chemi 
Doc Camera with Image Lab software (BioRad).
Statistics
All the data are presented as means ±SD of at 
least six independent experiments. Comparisons 
between study groups were determined by 
one-way ANOVA followed by the Tukeyow post-
hoc test. Calculations were performed using 
Statistica 10 (StatSoft, USA) software, and statis-
tical significance was established as P≤0.05.
RESULTS 
No cytotoxic effects were observed in the RAW 
264.7 cells treated with BaP, Chr, Flu, Baa for 2h 
and RvD2 for 30 min. Caspase -3/7 activity was 
mildly increased in the cells treated with BaP. 
Cell viability varied from 100% to 95% after incu-
bation with BaP for 2h. There were no apoptotic 
cells after treatment with the compounds.
Isoprostane content 
In control samples as well as the cells incubated 
with RvD2 there were no isoprostanes (Tab. 1). In 
RAW 264.7 cells treated with PAHs we detected 
all of the analyzed eicosanoids. The level of PGF2α 
varied from 0.8 to 1.3 ng/mL. The highest level of 
8-isoPGF2α was found in the macrophages after 
the exposure to BaP. Also higher concentrations of 
PGF3α, 8-isoPGF3α were noted. In the Chr and Flu 
samples we identified PGF3α and 8-iso PGF3α. The 
levels of those compounds were lower compared 
with the BaP samples. RvD2 incubation resulted 
in a statistically decreased concentration of all iso-
prostanes in cells after the exposure to BaP (Tab. 1). 
TABLE 1. The eicosanoid content [ng/mL] of RAW 264.7 cells after the exposure to PAHs and incubation with RvD2. 
Means ±SD, n=6. Asterisks denote statistically signifi cant differences, P<0.05.
8iPGF3α PGF3α 8iPGF2α PGF2α 5iPF2α
Control – – – – –
RvD2 – – – – –
BaP 1.3*±0.5 0.6* ± 0.0 2.5*± 0.4 1.3*± 0.2 0.5 ± 0.1
Chr – 0.4 ± 0.1 0.8 ± 0.2 – –
Flu – 0.3 ± 0.0 – – –
Baa – 0.6*± 0.1 0.8 ± 0.2 –
RvD2+BaP 0.5**±0.2 0.2**±0.0 0.6**± 0.2 0.2**± 0.0 –
RvD2+Chr – 0.3 ± 0.0 – – –
RvD2+Flu – – – – –
RvD2+Baa – 0.3**± 0.1 – – –
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COX-2, cPGES and FP-receptor expression
The highest amount of COX-2 compared with the 
control was observed in the RAW 264.7 cells incu-
bated with BaP. Higher expression of this protein 
was also observed in all the cells supplemented 
with other PAHs (p=0.01). The lowest expression 
of this protein was observed in the cells treated 
with PAHs and incubated with RvD2 (P=0.01) 
(Fig. 1A). The highest expression of cPGES pro-


Fig. 1. Relative expression of COX-2 (A), cPGES (B) and FP-receptor (C) in RAW 264.7 cells treated with PAHs and 
incubated with RvD2. Asterisks denotes statistically signifi cant differences, P<0.05.
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tein was observed in BaP-treated cells (P=0.02). 
After the exposure to PAHs and incubation with 
RvD2 the expression of this protein was statis-
tically significantly decreased (P=0.01) (Fig. 1B). 
In the samples incubated with PAHs and RvD2 
the level of the FP-receptor was statistically lower 
compared with the groups exposed to PAHs only 
(P=0.01) (Fig. 1C). 
DICUSSION
PAHs may exert negative effects on the human 
organism by inducing the oxidative stress. Lipid 
peroxidation has two major impacts on the cell. It 
changes the properties of the cellular membranes, 
affects their structure and the activity of mem-
brane-bound proteins, and it causes the forma-
tion of other reactive intermediates that propagate 
oxidative stress (KANG et al., 2010; KIM et al., 2013; 
JI et al., 2013). Among the markers of lipid peroxi-
dation, isoprostanes are considered to be the most 
reliable. They are formed by a free-radical attack 
on arachidonic acid localized in cellular mem-
branes. Currently, 8-iso prostaglandin F2α is the 
best characterized and the most often studied iso-
prostane (MILNE et al., 2006; BROOKS et al., 2008). 
The results of our investigation have shown that 
the exposure to PAHs and incubation with RvD2 
did not inhibit the growth and proliferation of RAW 
264.7 cells. In the control cell samples and in the 
cells supplemented with RvD2, isoprostanes were 
not found. In the RAW 264.7 cells supplemented 
with RvD2 with the addition of BaP, active lipid 
derivatives were identified. We detected lipid deriva-
tives from EPA (prostaglandin PGF3α and isopros-
tane 8-iPGF3α) as well as from arachidonic acid 
(8-iPGF2α and 5-iPF2α-VI). These findings strongly 
suggest that benzo(a)pyrene acts via cyclooxyge-
nase pathway (formation of PGF3α) and propagates 
oxidative stress by lipid oxidation. This observa-
tion is similar to the results of our previous study 
(GDULA-ARGASIŃSKA et al., 2013). Oxidative stress 
caused by lipid peroxidation through free radicals is 
believed to be one of the key factors underlying sev-
eral acute and chronic diseases which cause high 
morbidity and mortality, and oxidative stress has 
been implicated in the ageing process. 
The dietary intake of fatty acids affects pro-
duction of eicosanoids which are potent immune 
mediators being mainly synthesized from eicosa-
pentaenoic acid (EPA) and arachidonic acid (AA). 
Docosahexaenoic acid (DHA) and EPA are n-3 
PUFAs mainly derived from fish oils that competi-
tively inhibit n-6 PUFA arachidonic acid metabo-
lism, thus reducing generation of the inflammato-
ry leukotrienes and prostaglandins as well as the 
production of cytokines from inflammatory cells 
(GAO et al., 2006; KITZ et al., 2010; SERHAN, 2014).
While prostaglandins are produced as a result 
of cyclooxygenase enzyme activity, isoprostanes 
are generally thought to be formed non-enzymati-
cally by free radical-mediated peroxidation of ara-
chidonic acid and other unsaturated fatty acids. 
Separate evidence suggests that cyclooxygenase 
activity may also contribute to isoprostane produc-
tion in selected tissues. Due to the potential role of 
isoprostanes in the pathogenesis of a disease, their 
cellular signalling pathways and biological effects 
have been under investigation (DAVIDSON et al., 
2012; GDULA-ARGASIŃSKA et al., 2013, 2015a,b,c).
In the cells treated with PAHs, and then incu-
bated with RvD2, a decrease in COX-2, cPGES and 
FP-receptor expression was observed. The anti-
inflammatory properties of n-3 FAs and their pro-
resolving properties were observed in our previous 
studies. In the A549 cells supplemented with EPA 
or DHA and activated with lipopolysaccharide (LPS), 
maresin and protectin D1 and D2 were detected 
(GDULA-ARGASIŃSKA et al., 2015b). In another study, 
human hepatoma HepG2 cells were used to assess 
the effect of supplementation with EPA and treat-
ment with BaP. We observed the presence of lipid 
derivatives from EPA – Prostaglandin F3α (PGF3α), 
8-iso Prostaglandin F3α (8-isoPGF3α) as well as AA 
derivatives. We demonstrated that EPA has an anti-
oxidative stress effect under benzo(a)pyrene expo-
sure. Our findings strongly suggest that EPA plays 
a role in the enhancement of anti-oxidant defence 
(GDULA-ARGASIŃSKA et al., 2013). In the study of 
GDULA-ARGASIŃSKA et al., (2015c) it has been shown 
that supplementation of human epithelial cells 
A549 with EPA and DHA results in up- (AhR and 
PLA2G4A) and down-regulation (PTGS2) of genes 
and higher phospholipase A2 activity.
The results from the study of MERCHED et al., 
(2008) indicate that 12/15-lipoxygenase expres-
sion protects mice against atherosclerosis via 
its role in the local biosynthesis of lipid media-
tors, including lipoxin A4, resolvin D1, and pro-
tectin D1. These mediators exert potent agonist 
actions on macrophages and vascular endothelial 
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cells that can control the magnitude of the local 
inflammatory response (MERCHED et al., 2008; 
SEHRAN, 2014). Findings from the study of LEE et 
al. (2013) indicate that RvD1 expedites resolution 
of inflammation in macrophages through induc-
tion of efferocytosis by p50/p50-homodimer-
mediated repression of TNF-a production.
Alt ogether, our findings provide a novel mech-
anism underlying the detrimental effects of PAHs 
and RvD2 on macrophages which might play 
a critical role in inflammatory disease states. 
Our results suggest that RvD2 plays a role in 
enhancement of the anti-oxidant, anti-inflamma-
tory and pro-resolving activities and has a high 
therapeutic value and therefore should be one of 
the therapeutic approaches due to its dynamically 
modulatory properties.
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